IP Library Granted Patent US 12,478,640
Granted Patent B2
US 12,478,640 · App. 17/412,241 · Granted Nov 25, 2025

Inhalation of nitric oxide for treating respiratory diseases

Inventors: Yossef Av-Gay (Vancouver, CA); Christopher C. Miller (N. Vancouver, CA); David Greenberg (Omer, IL)
Assignee: BEYOND AIR LTD
A61K33/00A61B5/0833A61B5/0836A61B5/14507A61B5/14542A61B5/4244A61K9/007A61M16/0003A61M16/12A61M16/122A61M2202/0007A61M2202/0275A61M2205/3303A61M2230/202A61M2230/205A61M2230/207A61M2230/432
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,478,640
App. No.
17/412,241
Granted
Nov 25, 2025
Kind
B2
Abstract

A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.

Claims (2)

1 . A method of treating an infant suffering from bronchiolitis associated with respiratory syncytial virus (RSV), the method comprising administering to the infant via inhalation at least 160 ppm±10% gaseous nitric oxide (gNO) for 30 minutes, 5 times per day for up to 5 days, wherein there is a time period from 3 to 5 hours between gNO administrations.

2 . The method of claim 1 , wherein the infant is an immuno-compromised infant.

Assignments (2)
SECURITY INTEREST Recorded Nov 24, 2025
From: BEYOND AIR LTD
To: STREETERVILLE CAPITAL, LLC
Reel/Frame 073017/0112 →
CHANGE OF NAME Recorded Aug 12, 2022
From: ADVANCED INHALATION THERAPIES (AIT) LTD.
To: BEYOND AIR LTD
Reel/Frame 061164/0767 →